探讨影响厄洛替尼治疗晚期非小细胞肺癌预后的因素  

Explore the Prognostic Factors of Advanced NSCLC Patients Treated with Erlotinib

作　　者：杨芳[1] 王萌[1] 杨朝阳[1] 洪璇[1] 陈公琰[1] 

机构地区：[1]哈尔滨医科大学附属第三医院内一科,哈尔滨150081

出　　处：《实用肿瘤学杂志》2012年第1期92-96,共5页Practical Oncology Journal

摘　　要：目的 探讨影响厄洛替尼治疗晚期非小细胞肺癌预后的临床因素.方法 收集55例厄洛替尼治疗晚期非小细胞肺癌患者的临床资料,分析临床特征与PFS、OS的关系.结果 血清LDH升高及0-1度皮疹是不良预后的独立危险因素.结论 血清LDH水平是否正常与皮疹是否严重是影响厄洛替尼治疗晚期NSCLC患者预后的重要因素.Objective The aim of this study is to explore the prognostic factors of advanced NSCLC pa- tients treated with erlotinib. Methods Clinical characteristics of fifty - five advanced NSCLC patients treated with erlotinib were collected. The association of their clinical characteristics with median progression - free survival time （PFS） and overall survival（OS） was analysed. Results High serum LDH level and grade 0 - 1 rash were independent risk factors for bad prognostic in patients. Conclusion Serum LDH level and grade of rash are important prognostic factors in advanced Non - small Cell Lung Cancer treated with erlotinib.

关 键 词：厄洛替尼 晚期非小细胞肺癌 预后因素 

分 类 号：R734.2[医药卫生—肿瘤]